BridgeMD
New treatment option for Colorectal Cancer
Official title Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
ClinicalTrials.gov ID: NCT05797467
What this study is testing
What is FOLFOX chemotherapy regimens?
FOLFOX chemotherapy regimens is an investigational medicine, being studied as a potential treatment for colorectal cancer.
Also referred to as CapeOx regimens.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (DFS) compared to adjuvant chemotherapy alone.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Both sexes, aged 18-75 years;
- Pathologically confirmed pT3-4N2 stage colorectal adenocarcinoma after surgery;
- ASA grade \< IV and/or ECOG performance status score ≤ 2 points;
- Fully understand and voluntarily sign the informed consent form for this study.
You likely can't join if
- A history of other malignant tumors;
- Patients with severe liver, kidney, cardio-pulmonary, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy;
- Patients allergic to any component in the study;
- Patients with severe uncontrollable recurrent infections or other severe uncontrollable concurrent diseases;
- Patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other...
- Patients with emergent surgery due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc.;
See the full eligibility criteria
- Both sexes, aged 18-75 years;
- Pathologically confirmed pT3-4N2 stage colorectal adenocarcinoma after surgery;
- ASA grade \< IV and/or ECOG performance status score ≤ 2 points;
- Fully understand and voluntarily sign the informed consent form for this study.
- A history of other malignant tumors;
- Patients with severe liver, kidney, cardio-pulmonary, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy;
- Patients allergic to any component in the study;
- Patients with severe uncontrollable recurrent infections or other severe uncontrollable concurrent diseases;
- Patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases requiring comprehensive treatment (including mental...
- Patients with emergent surgery due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc.;
- Patients with a history of severe mental illness;
- Pregnant or lactating women;
- Patients with other clinical or laboratory conditions that the investigators consider inappropriate for participation in this trial.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.